ABSTRACT
Description: Ibritumomab is a murine derived IgG1 kappa monoclonal antibody specific for the human CD20 antigen, which is expressed on the surface of normal and malignant B cells. Ibritumomab is used coupled to the radioisotopes Indium-111 (In-111) and Yttrium-90 (Y-90), via the linker-chelator tiurexan and in combination with the recombinant chimeric monoclonal antibody Rituximab. Ibritumomab is produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology. Zevalin is presented in separate kits for the preparation of intravenous administration of In-111 ibritumomab tiuxetan or Y90 ibritumomab tiuxetan.
